Michael Kauffman is a seasoned drug developer, board member, and physician scientist. They served as Chief Medical Officer at Onyx Pharmaceuticals and Proteolix Pharmaceuticals, and held CEO positions at Predix Pharmaceuticals Inc. and EPIX Pharmaceuticals. Currently, Kauffman is the CEO and President of Nereid Therapeutics and chairs the boards of Incendia Therapeutics and BiVictriX Therapeutics, among other roles. Their medical training includes an Internal Medicine residency and Rheumatology fellowship at Harvard Teaching Hospital and Massachusetts General Hospital, respectively, after earning their degree at Johns Hopkins School of Medicine. Kauffman continues to contribute to multiple organizations, including Kezar Life Sciences and Verastem Oncology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices